跳至主要内容
临床试验/NCT03636464
NCT03636464招募中不适用

Pharmacokinetics and Deposition of Commonly Prescribed Antibiotics in Hospitalized Critically Ill Patients Undergoing Renal Replacement Therapies

Cleveland Clinic Abu Dhabi1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2018年4月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
200
试验地点
1
主要终点
Serum antibiotic concentrations over time during dose interval

研究概览

简要总结

The study is aiming to describe the pharmacokinetic and pharmacodynamic profile of intravenous meropenem, ertapenem, cefepime, colistin, Ceftazidime/Avibactam , Ceftolozane/Tazobactam , and piperacillin/tazobactam in the plasma and determine how much is removed by Renal Replacement Therapies to ensure adequate dosing

详细描述

This pharmacokinetic evaluation and clinical outcomes will be an open-label study of 12-16 adult patients/antibiotic dose/modality to a total number of 180-240 patients, admitted to the acute care levels or intensive care unit at Cleveland Clinic Abu Dhabi receiving RRT and prescribed these seven antibiotics as recommended by their treating physicians. The collection of blood, ultrafiltrate or effluent fluids depending on RRT modality (HD or CRRT), and urine samples will begin after participants are administered first dose to determine if a loading dose will be required then after at least three doses (as prescribed by the treating physician) once these drugs will be at steady-state concentration. The study intervention duration will depend on dialysis modality expected to be 3 to 5 days depending on RRT modality and patients will be followed for outcomes (death or cure). Collected blood, effluent and urine samples will be assayed for drug concentration. The concentration data will be modeled by a computer program to determine the pharmacokinetic parameters used to predict future dosing in the case of RRT. Linear/logistic regression will be used as a component of statistical analysis to model the relationship between CRRT machine settings and the amount of the study drugs that will be removed by the filter. Information related to adverse events , clinical and microbiological cure will be collected in case report forms.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adults > 18 year old
  • Prescribed meropenem, ertapenem, cefepime, colistin, Ceftazidime/Avibactam , Ceftolozane/Tazobactam , or piperacillin/tazobactam for treatment of infection as part of standard medical care
  • Administered meropenem, ertapenem, cefepime, colistin, Ceftazidime/Avibactam , Ceftolozane/Tazobactam ,or piperacillin/tazobactam while on renal replacement therapy (IHD or CRRT) or renal replacement therapy started while on any of these antibiotics
  • Patients with hemoglobin > 70 g/L without blood transfusion in the past 24 hours
  • Informed consent given by patient, next of kin or legally authorized representative

排除标准

  • Less than 18 years of age
  • Pregnant females
  • Body mass index < 18 or > 35 kg/m2
  • Presence of anemia (defined as hemoglobin < 70 g/L), thrombocytopenia, or leukopenia as defined by hematocrit, platelet, or white blood cell count < 75% of the lower limit of normal
  • Concomitant receipt of another cephalosporin interfering with assay
  • Participants likely to require surgical interventions during the study period if the surgery would interfere with dosing intervals or affect sampling process
  • Protected patients; prisoners, patients with HIV, patients with physical or mental disabilities, psychiatric patients.
  • Patients with documented life-threatening allergy (i.e anaphylaxis, angioedema) to any of the study drugs or their class.
  • Patients with conditions known to significantly affect PK; (i.e. severe burn, significant ascites, spinal cord injury and cystic fibrosis)
  • Any other reason felt by the investigators to potentially affect the outcomes of the study

结局指标

主要结局

Serum antibiotic concentrations over time during dose interval

时间窗: 24 months

Blood will be collected at designated time points, serum samples will be assayed for drug concentration over time to describe pharmacokinetic disposition

次要结局

  • Area under concentration time curve over minimum inhibitory concentration for (Cmax/MIC) for concentration dependent antibiotics(24 months)
  • Amount of antibiotic removed by dialysis(24 months)
  • Time above minimum inhibitory concentration (T/MIC) for time dependent antibiotics(24 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Wasim El Nekidy

Senior Pharmacotherapy Specialist

Cleveland Clinic Abu Dhabi

研究点 (1)

Loading locations...

相似试验